Benitec Biopharma

March 3, 2016May 20, 2016

Benitec Biopharma to Terminate Hepatitis C Trial Due to Competing Therapies

News

Sydney, Australia-based Benitec Biopharma has announced it will terminate its hepatitis C program because the company has concluded TT-034 is no longer commercially viable to bring to market. But the program won’t be discontinued until ... Read more

September 29, 2015September 29, 2015

Benitec Biopharma Adds Fourth Site for Hepatitis C Clinical Trial for TT-034

News

Clinical stage biotechnology company, Benitec Biopharma Ltd., recently announced it has opened a 4th additional site to carry out ongoing Phase 1/2a studies on TT-034, a novel treatment for Hepatitis C ... Read more

June 2, 2015June 2, 2015

Benitec Biopharma Signed Manufacturing Deal For Hepatitis C Treatment

Hepatitis C, News

Benitec Biopharma recently announced an agreement with Omnia Biologics, a Maryland-based biotechnology company, to manufacture materials for the TT-034 trial, the first-in-man clinical trial for hepatitis C treatment. The agreement was ... Read more

January 21, 2015January 21, 2015

Benitec Biopharma Advances Hepatitis C Clinical Trial

News

Benitec Biopharma Limited announced that it has dosed the third patient in its Phase I/IIa clinical trial with TT-034 for hepatitis C, at the Duke Clinical Research Unit (USA). This marks an ... Read more